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ABSTRACT
CONTEXT: Primary malignancy in giant cell tumor (PMGCT) is rare. It is defined as a high-grade sarcoma originating in a giant cell tumor (GCT) and seems 
to behave less aggressively than its secondary counterpart does. 
CASE REPORT: This report presents the case of a 39-year-old female with pain in her left shoulder for one month. Radiography showed a pathological 
fracture of the proximal humerus associated with an osteolytic lesion. Histopathological analysis showed typical areas of GCT juxtaposed with a 
sarcomatous component. 
CONCLUSIONS: PMGCT seems to behave less aggressively than secondary malignancy in GCT, and it may simulate its more common benign counterpart 
clinically and radiographically. However, it requires a more aggressive type of treatment.
RESUMO
CONTEXTO: Malignização primária no tumor de células gigantes (MPTCG) é rara. Ela é definida como um sarcoma de alto grau originário de um tumor de 
células gigantes que parece ser menos agressivo que o tipo secundário. 
RELATO DE CASO: Relatamos um caso de uma paciente de 39 anos de idade, com dor no ombro esquerdo há um mês. A radiografia mostrou uma fratura 
patológica do úmero proximal associada a uma lesão osteolítica. O exame histopatológico revelou típicas áreas de tumor de células gigantes justapostas 
por um componente sarcomatoso. 
CONCLUSÃO: MPTCG parece se comportar menos agressivamente que a neoplasia secundária do tumor de células gigantes (TCG), e pode simular o TCG, 
que é mais comum, tanto clínica como radiograficamente. Entretanto, exige tratamento mais agressivo.
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INTRODUCTION
Giant cell tumor (GCT) is a primary locally aggressive bone neoplasm 
characterized by stromal mononucleated cells associated with uniformly 
distributed osteoclast-like giant multinucleated cells. This tumor type ac-
counts for 4-5% of all primary bone tumors and 20% of benign bone tu-
mors.1 Skeletally mature patients ranging from 20 to 45 years of age, espe-
cially women, are affected. GCT usually involves the epiphyseal or meta-ep-
iphyseal region of long bones, particularly the femur and tibia, and appears 
radiographically as a purely osteolytic eccentric lesion.2 Malignancy in GCT 
(MGCT) cases is defined as high-grade sarcomas originating in a GCT (pri-
mary) or at the location of a previous well-documented GCT (secondary).1 
Primary malignancy in GCT (PMGCT) is the rarest type, and it seems to 
behave less aggressively than the secondary type does.3,4
Here, we report the clinicopathological features of a rare case of 
PMGCT that was treated by the Orthopedic Oncology Group at a ref-
erence service, and we briefly review the pertinent literature. 
CASE REPORT
A 39-year-old female presented with pain in her left shoulder for 
one month. Clinical examination revealed slight swelling and tender-
ness of the proximal part of the left upper limb, with unremarkable 
neurological examination. No calcium metabolism abnormality was 
identified. Plain X-rays showed a pathological fracture of the proximal 
humerus associated with an osteolytic lesion (Figure 1). Scintigraphic 
evaluation revealed a lesion with high uptake. An incisional biopsy was 
performed and the diagnosis of GCT was made. 
Microscopic examination showed typical areas of GCT character-
ized by stromal mononucleated cells, which were associated with uni-
formly distributed osteoclast-like giant multinucleated cells (Figure 2), 
in which the nuclei of the stromal cells were identical to the nuclei of 
the giant cells. Juxtaposed to these areas, there was a sarcomatous com-
ponent composed of anaplastic spindle cells showing pleomorphism, 
nuclear hyperchromasia, increased nuclear/cytoplasmic ratio and atypi-
cal (tri-multipolar) mitotic figures (Figure 3). There was predominance 
of atypical stromal spindle cells over the giant cells, as well as osteoid 
matrix synthesis by these atypical spindle cells (osteogenic sarcoma/os-
teosarcoma), thereby giving the diagnosis of PMGCT of the “dediffer-
Figure 1. Radiograph of the left shoulder showing a pathological fracture 
of the proximal humerus. Note an osteolytic lesion located in the meta-
epiphyseal region of the bone.
Figure 2. Photomicrograph showing typical areas of giant cell tumor 
characterized by stromal mononucleated cells associated with uniformly 
distributed osteoclast-like giant multinucleated cells (200 x, hematoxylin 
and eosin, HE). 
Figure 3. Photomicrograph showing a juxtaposed sarcomatous component 
(200 x, hematoxylin and eosin, HE).
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entiated” type. Foci of coagulative necrosis were observed as well. The 
mitotic index was up to 23 mitoses/10 high-power fields (HPF). Signifi-
cant areas of the lesion were represented by the sarcomatous component 
(70-80%). Vascular emboli were also observed. 
Wide resection was performed, with reconstruction using an endo-
prosthesis (Figure 4). After the operation, adjuvant chemotherapy based 
on the protocol used for osteosarcoma was provided. After four years of 
follow-up, the patient has no clinical or radiological evidence of recur-
rence.
DISCUSSION
Primary malignancy in GCT (PMGCT) is rare and represents less 
than 1% of GCT.1,3-5 Likewise, the case reported here accounted for 
0.22% of 435 cases treated in our service over a 53-year-period This 
case was accepted as PMGCT since it showed typical areas of GCT 
(osteoclast-like giant multinucleated cells uniformly distributed among 
stromal mononucleated cells with nuclei similar to the nuclei of the gi-
ant cells) juxtaposed with areas of high-grade sarcoma represented by an 
osteogenic sarcoma (osteosarcoma). 
Recently, the term “malignancy in giant cell tumor” has been pre-
ferred for GCT cases that show sarcomatous areas synchronously (pri-
mary) or that are replaced by a malignant component metachronously 
(secondary).6 “Malignant giant cell tumor” is a non-specific term used 
in the past for different neoplasms with giant cells, such as “giant cell-
rich” osteosarcoma, malignant fibrous histiocytoma with giant cells and 
GCT with different degrees of anaplasia or with metastasis.3
The histopathological classification criteria for the sarcomatous 
component in PMGCT are not well established in the literature. Origi-
nally, Jaffe7 described morphology in which the stromal mononucleat-
ed cells showed noticeable atypia (Grade III). Subsequently, Nascimen-
to et al.4 proposed that there should be significant areas of high-grade 
non-osteogenic sarcoma, thereby avoiding misdiagnosis of “giant cell-
rich” osteosarcomas as PMGCT. Recently, not only has it been possible 
for the sarcomatous component to be either osteogenic (osteosarcoma) 
or non-osteogenic (malignant fibrous histiocytoma/fibrosarcoma), but 
also, analogous to the dedifferentiation process of tumor progression 
seen in liposarcomas,8 chondrosarcomas,9 chordomas10 and parosteal 
osteosarcomas,11 the expression “dedifferentiated giant cell tumor” has 
been applied to PMGCT cases in which the malignant component is 
not represented by areas morphologically reminiscent of a GCT (Jaffe 
and Lichtenstein’s grade III GCT).5,12
The diagnosis of PMGCT may be extremely difficult.1 Pleomor-
phism and some degree of cell atypia, which is considered degenerative 
in nature,13 as well as areas of coagulative necrosis, vascular emboli and 
metastasis,6 are not considered to be criteria for malignancy.1 The differ-
ential diagnosis with “giant cell-rich” or “osteoclast-rich” osteosarcoma 
in a tumor in which the cells synthesize osteoid and are associated with 
osteoclast-like giant multinucleated cells may be achieved through the 
absence of typical GCT areas and through a diaphyseal or meta-dia-
physeal location.14 On the other hand, malignant fibrous histiocytomas 
with giant cells are characterized by a storiform pattern without a GCT 
component.
Although the histogenesis of GCT is still unknown, there is specula-
tion about it. Brien et al.15 suggested a hypothetic model with three cell 
types: mesenchymal, spindle, and mononucleated and multinucleated 
histiocytic types. Initially, there would be proliferation of the mesenchy-
mal component with production of high levels of osteoclast stimulator/
activator factors. In response, the histiocytic cells would fuse into the os-
teoclast-like multinucleated giant cells. Rarely, the primitive mesenchy-
mal component would dedifferentiate and originate a high-grade sarco-
ma (osteo/fibrosarcoma, or malignant fibrous histiocytoma), thus char-
acterizing PMGCT. This phenomenon might be time-dependent,12,16 or 
even associated with degenerative cellular events, since PMGCT affects 
patients one1,2 to three decades3,4 later. 
Similarly to GCT, PMGCT presents as a painful lesion that typical-
ly involves the ends of the long bones, in a way that might be impossible 
to differentiate it clinical and radiographically from an ordinary GCT.12 
The differential diagnosis is essential, since GCT is a potentially curable 
neoplasm that carries five-year overall survival of about 90%.17,18 None-
theless, it has locally aggressive behavior, since the recurrence rates range 
from 6.3 to 33%18-20 depending on the treatment,21 and it might even 
be fatal.2 Primary malignancy in GCT, however, is a sarcoma that seems 
to behave less aggressively than the secondary type of MGCT, especially 
when the latter is related to prior radiotherapy.2-4
No mainstay therapy has yet been established, since this is an ex-
tremely rare entity. Wide surgical resection has been recommended. 
Figure 4. Radiograph showing wide resection of the proximal humerus with 
endoprosthesis replacement. 
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There is some evidence that surgery associated with chemotherapy is 
more efficient than surgical resection alone.12
CONCLUSION
Primary malignancy in giant cell tumor seems to behave less ag-
gressively than secondary malignancy in giant cell tumor, as has been 
reported in the literature. It is essential to recognize this rare entity mi-
croscopically, since it may simulate its more common benign counter-
part clinical and radiologically. However, differently, it requires a more 
aggressive type of treatment. 
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